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Leptin enhances the glucose utilization in most insulin target tissues and paradoxically decreases it in
white adipose tissue (WAT), but knowledge of the mechanisms underlying the inhibitory effect of
central leptin on the insulin-dependent glucose uptake in WAT is limited. After 7 d intracerebroven-
tricular leptin treatment (0.2g/d) of rats, theoverall insulin sensitivity and the responsiveness ofWAT
after acute in vivo insulin administration were analyzed. We also performed unilateral WAT dener-
vation to clarify the role of the autonomic nervous system in leptin effects on the insulin-stimulated
[3H]-2-deoxyglucose transport in WAT. Central leptin improved the overall insulin sensitivity but de-
creased the in vivo insulin action in WAT, including insulin receptor autophosphorylation, insulin
receptor substrate-1 tyrosine-phosphorylation, and Akt activation. In this tissue, insulin receptor sub-
strate-1 and glucose transporter 4mRNA and protein levels were down-regulated after central leptin
treatment. Additionally, a remarkable up-regulation of resistin, togetherwith an augmented expres-
sion of suppressor of cytokine signaling 3 inWAT,was also observed in leptin-treated rats. As a result,
the insulin-stimulated glucose transporter 4 insertion at the plasma membrane and the glucose
uptake inWATwere impaired in leptin-treated rats. Finally, denervation ofWAT abolished the
inhibitory effect of central leptin on glucose transport and decreased suppressor of cytokine
signaling 3 and resistin levels in this tissue, suggesting that resistin, in an autocrine/paracrine
manner, might be a mediator of central leptin antagonism of insulin action in WAT. We
conclude that central leptin, inhibiting the insulin-stimulated glucose uptake in WAT, may
regulate glucose availability for triacylglyceride formation and accumulation in this tissue,
thereby contributing to the control of adiposity. (Endocrinology 152: 1366–1377, 2011)
Leptin modulates glucose homeostasis, acting throughboth central and peripheral pathways, as an insulin-
sensitizing factor at the whole-body level (1, 2). Never-
theless, studies on glucose uptake by different tissues after
in vivo leptin treatment suggest that the hormone exerts
tissue-specific effects, stimulating glucose utilization in
brown adipose tissue, heart, and skeletal muscle but in-
hibiting glucose uptake in white adipose tissue (WAT) (3,
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4). However, studies concerning the effects of leptin on
insulin signaling in WAT have been not only scarce, but
also controversial (5).
Whereas leptin microinjection into ventromedial hy-
pothalamus decreases the insulin-stimulated glucose up-
take in WAT (6), leptin incubation of isolated adipocytes
has been reported to inhibit insulin stimulation of glucose
transport (7), to impair only the lipogenic action of insulin
(8, 9), and not to influence insulin-mediated effects (10,
11). Additionally, we have reported that in vivo chronic
leptin administration impairs insulin-stimulated MAPK
activity in isolated adipocytes (12), whereas the insulin-
stimulated MAPK phosphorylation in WAT was in-
creased after acute in vivo leptin treatment (13). Taken
together, these data strongly suggest a complex regulatory
cross talk between leptin and insulin signaling pathways.
Several studies have suggested that the WAT plays a
pivotal role in regulating overall insulin sensitivity, al-
though the mechanisms involved are still poorly under-
stood. Thus, decreasing visceral fat by caloric restriction
(14) or surgical removal (15) prevents the development of
overall insulin resistance. Adipose-selective glucose trans-
porter 4 (GLUT4) gene disruption causes glucose intoler-
ance and hyperinsulinemia (16), whereas GLUT4 overex-
pression in fat tissue enhances whole-body insulin
sensitivity and glucose tolerance in diabetic mice (17). Fi-
nally, the overexpression in WAT of suppressor of cyto-
kine signaling 3 (SOCS3), known for its insulin inhibitory
effects (18), causes local but not systemic insulin resistance
(19). In fact, an increased SOCS3 expression in adipocytes
had been proposed as a potential mediator of the insulin
resistance induced by several hormones and cytokines, in-
cluding leptin, insulin, TNF-, and resistin (12, 20–22).
Compelling evidence suggests that leptin exerts its met-
abolic effects predominantly through different hypotha-
lamic nuclei, where the leptin receptor expression is the
highest compared with other tissues (23). By acting on the
brain, leptin affects appetite, neuroendocrine pathways,
and autonomic nerves,which transmit the hormone signal
to the periphery (24). On the other hand, direct leptin
effects have been reported in peripheral tissues that ex-
press the leptin receptor (5). However, the relative impor-
tance of peripheral vs. central actions of leptin on meta-
bolic effects of the hormone is not well characterized.
Hence, the overall objective of the present work is to
study the molecular mechanisms by which central leptin
treatment impaired insulin-stimulated glucose uptake in
WAT. To this end, we analyzed the effects of chronic cen-
tral leptin infusion on early steps of the insulin signaling
pathway implicated in glucose uptake inWAT.The role of
SOCS3 and resistin as mediators of central leptin action
regulating glucose availability for fatty acid esterification
in this tissue arediscussed.Thiswork extendsourprevious
observations examining the effects of in vitro and/or in
vivo leptin administration on insulin signaling in isolated
adipocytes (12).
Materials and Methods
Male 3-month-old Wistar rats were randomly housed in indi-
vidual cages under conditions of climate-controlled quarters
with a 12-h light cycle and fed ad libitum standard laboratory
diet and water. The animals were handled according to the laws
of the European Union and the guidelines of the National Insti-
tutes of Health, and the experimental protocols were approved
by the institutional committee of bioethics.
WAT denervation
Unilateral autonomic nervous system denervation of the ret-
roperitoneal fat pad (rWAT) was performed according to Kreier
et al. (25). As we previously reported (26), local denervation in
anesthetized rats, as below, was achieved by surgical removing
nerves running along blood vessels from the diaphragm to the
superior tip of the left rWAT, with the contralateral intact right
pad used as control. Five weeks after the surgery, rats were sub-
jected to an intracerebroventricular leptin administration as de-
scribed below. In agreement with previous reports (27) and sup-
porting the efficiency of the surgical denervation, the weight of
the denervated left rWAT increased by 27%, and the total
norepinephrine (NE) content in the denervated fat pad was sig-
nificantly reduced compared with the contralateral intact right
pad (5.5 0.4 vs. 9.7 0.3 ng NE/g tissue, respectively; n 3;
P  0.001).
Leptin administration
Intracerebroventricular leptin administrationwas performed
as previously described (28). Briefly, rats were anesthetized with
ip ketamine/diazepam/atropine used at 50 mg/kg, 4 mg/kg, and
0.2 mg/kg, respectively (Parke-Davis, Roche and Braun, Spain),
and placed in a stereotaxic frame (David Koppf, Tujunga, CA).
An opening in the skull wasmadewith a dental drill at1.6mm
lateral to themidline and0.8mmposterior to bregma.A cannula
connected to an osmotic pump (Alzet, Palo Alto, CA) was im-
planted in the right lateral cerebral ventricle,with a releasing rate
of 1 l/h, and filled with 0.0082 g/l (0.2 g/d) rat leptin (Sig-
ma-Aldrich, St. Louis, MO), or its vehicle (PBS). Five groups of
rats randomly distributed were investigated: 1) rats infused with
leptin (Lep); 2) rats infused with vehicle and allowed to eat ad
libitum (SS); 3) rats infused with vehicle and pair-fed to the
amount of food consumed by the leptin-infused animals (PF); 4)
unilateral denervated rats infused with leptin, and 5) unilateral
denervated pair-fed rats infused with vehicle. After 7 d of treat-
ment ratswere killed by decapitation or subjected to an iv insulin
(10 I.U/kg body weight) (Lily) or saline injection for 30 min and
then killed by decapitation. rWAT and epididymal fat pads
(eWAT) were dissected and weighed. An aliquot (per triplicate)
from each fat padwas immediately used, independently, for glu-
cose transport experiments as tissue explants. The rest of the
tissue was flash frozen in liquid nitrogen and stored at 70 C
until use. NE tissue content was measured using a NE research
ELISA kit (Demeditec Diagnostics GmbH, Kiel, Germany), fol-
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lowing themanufacturer’s instructions. Plasma triacylglycerides
(TAG), glucose, and TAG content in WAT were determined as
previously described (29). Plasma leptin and insulin levels were
assayed using specific rat kits from Spi-Bio (Montigny le Bret-
onneaux, France). Plasma resistin was assessed using a rat resis-
tin ELISA kit (BioVendor, Brno, Czech Republic), following the
manufacturer’s instructions.
Glucose tolerance tests
Intraperitoneal glucose tolerance tests were performed in
overnight-fasted animals as described (26). Rats from groups
1–3 were weighed and injected ip with 2 g of glucose/kg body
weight. Blood samples were obtained from the tail tip at 0, 15,
30, 60, and 120 min after glucose administration, and glucose
levels were determined using an Accutrend Glucose Analyzer
(Roche Diagnostics Corp., Indianapolis, IN). Plasma insulin
levels were determined as above. Overall changes in glucose
and insulin during glucose tolerance test were calculated as the
area under the curve (AUC) using the GraphPad Prism version
3.03 for Windows (GraphPad Software). The ratio of glucose
AUC to insulin AUC was used as an index of whole body
insulin sensitivity (30).
Glucose uptake in WAT explants
Glucose uptake was determined, independently, in rWAT
and/or eWAT. Fat pad explants (approximately 20mg), exclud-
ing visible connective tissue and blood vessels, were placed im-
mediately after dissection in 0.5mlKrebs-Ringer-HEPES (KRH)
(pH 7.4) supplemented with 1.2 mM CaCl2 and 2% BSA (KRH/
Ca2-BSA). To analyze the effect of resistin (26–49, mouse re-
sistin, Phoenix Pharmaceuticals Inc, Belmont, CA) on glucose
uptake, WAT explants from control ad libitum rats were prein-
cubated at 37C in the absence or presence of resistin (200 ng/ml)
for 4 h in 0.5 ml KRH/Ca2-BSA supplemented with 5.0 mM
pyruvate before insulin stimulation. All explants were incubated
in the absence or presence of 80 nM insulin for 10 min at 37 C.
2-Deoxyglucose (0.2 mM) and [3H]-2-deoxyglucose (2 Ci/ml)
(Amersham Pharmacia Biotech) were then added to the explants
and incubated a further 10min at 37C. Explantswere incubated
with the transport stop solution (50 M Cytochalasin B, 5 mM
D-glucose) for 10min at 37 C andwashed twice in ice-cold KRH
buffer to remove unbound label. Explants were dissolved in
NaOH 1N, SDS 0.1%, at 50 C for 2 h, and radioactivity was
determined using a Beckman Scintillation counter. Basal glucose
uptake was taken as 2-deoxyglucose uptake in the absence of
insulin. Data were expressed as pmol 2-deoxyglucose/mg wet
weight. The small amount of extracellular 2-deoxyglucose re-
maining was corrected from the [3H]-2-deoxyglucose content in
samples incubatedwith the transport stop solution for 10min at
37 C before the transport reaction.
Real-time RT-PCR
Total RNAwas isolated from eWAT and/or rWAT using the
Trizol reagent (Invitrogen, Carlsbad, CA). The cDNA was syn-
thesized from1.5gofDNase-treatedRNAbyusing the reverse-
transcriptase activity fromMoloneymurine leukemia virus (Life
Technologies, Inc.-BRL,Carlsbad,CA), andp[dN]6 (Boehringer
Mannheim, Germany) as random primer. Relative quantitation
of insulin receptor (IR)-A, IR-B, insulin receptor substrate
(IRS)-1, GLUT4, SOCS3, and resistin gene expression was per-
formed by TaqMan real-time PCR according to the manufac-
turer’s protocol on an ABI PRISM 7500 FAST Sequence Detec-
tion System instrument and software (PE Applied Biosystem,
Foster City, CA). IRS-1, GLUT4, SOCS3, and resistinweremea-
suredusingPre-DevelopedTaqManAssayReagents (PEApplied
Biosystem). For IR-B, the primers and probe sets were designed
using the manufacturer’s software and sequences available in
GenBank (M29014). The probe was 5-TCTTCAGGCAATG-
GTGCT-3 and spanned 18 nucleotides from the exon 11. For
IR-A the primers used were 5-CCCACCTTTTGAGTCTGAC-
GAT-3 and 5-GGGATGGCCTGGGAACA-3, flanking a
fragment of 182bp.Todetermine the accumulationof IR-APCR
product, SYBRGreen dye was used as a real-time reporter of the
presence of double-stranded cDNA.
To normalize the amount of sample cDNA added to the re-
action, amplification of endogenous control 18S rRNA was in-
cluded in separate wells using VIC (TaqMan Assay) or SYBR
Green as real-time reporter. The CT method was used to cal-
culate the relative differences between experimental conditions
and control groups as fold change in gene expression (31).
Subcellular fractionation and immunoblot analysis
The tissue was homogenized in 2 volumes of isolation me-
dium [250 mM sucrose, 10 mMHEPES (pH 7.4), 1 mM EDTA, 2
mM EGTA, 5 mM NaN3, 5 mM NaF, 1 mM phenylmethylsulfo-
nylfluoride, 2 mMNa3VO4, 10 g/ml leupeptin, 10 g/ml apro-
tinin, 1 g/ml pepstatin], centrifuged at 450	 g for 5 min, and
the infranadant was considered as total extract. The purified
TABLE 1. Effects of central leptin administration on the biological characteristics of the animals
Treatment SS PF Lep
Initial body weight (g) 353  10a 372  20a 359  13a
Final body weight (g) 380  13a 359  11b 344  8b
Daily food intake (g) 19  1a 13  1b 13  1b
Epididymal WAT weight (g) 5.5  0.3a 5.0  0.4a 3.7  0.6b
Retroperitoneal WAT weight (g) 4.9  0.4a 4.6  1.1a 2.9  0.4b
TAG in WAT (mg/g tissue) 18.3  0.6a 19.4  1.1a 15.7  0.2b
Plasma TAG (mg/dL) 68.2  8.2a 64.7  5.6a 44.3  5.9b
Plasma glucose (mM) 6.5  0.8a 5.9  0.4a 5.9  0.6a
Plasma insulin (ng/ml) 1.6  0.5a 1.4  0.1a 0.7  0.1b
Plasma leptin (ng/ml) 5.9  0.5a 5.4  1a 5.2  0.8a
Plasma resistin (ng/ml) 21  1a 24  2a 18  2a
After 7 d of central leptin (Lep) 0.2 g/d or vehicle (SS or PF) infusion, glucose, insulin, leptin, and resistin were assessed in plasma. Results are the
mean  SEM of four to ten rats per group. Values that do not share the same superscript letter are significantly different (P  0.05).
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plasma membrane (PM), light membranes (LM), and the cyto-
solic fraction (CYT) were obtained as described previously (32).
Membrane protein concentrations were determined using the
bicinchoninic (BCA) protein assay kit fromPierce Biotechnology
(Cultek, Spain). As we have previously reported (26), -actin,
Na/K-ATPase, and TGN38 were used as controls for protein
loading of the total tissue extract, PM, and LM fractions, re-
spectively (data not shown). Samples from all experimental con-
ditions were run on the same gel, immunoblotted, and detected
as previously described (33). Primary polyclonal antibodieswere
anti-phospho-IR (Tyr1146), anti-IRS-1, anti-phospho-IRS-
1(Ser307) (Cell Signaling, Beverly, MA), anti-IR, anti-SOCS3,
anti-phospho-Akt (Thr308) (Santa Cruz Biotechnology), anti-
Akt2/PKB (Upstate Biotechnology), anti-resistin (Chemicon),
monoclonal antibodies anti-phospho-tyrosine, anti-phospho-
Akt (Ser473) (Cell Signaling), anti-GLUT4 (IF8) (Biogenesis), an-
ti-Na/K-ATPase, anti-TGN38, and anti-
-actin (Abcam, Cambridge, UK). The
densitometric values of IR-PY, IRS-1-PY,
IRS-1-PS, Akt-PS, or Akt-PT were normal-
ized to the densitometric values of the cor-
responding amount of protein mass in the
same sample.Datawere expressed as a ratio
of IR-PY/IR, IRS-1-PY/IRS-1, IRS-1-PS/
IRS-1, Akt-PS/Akt2, and Akt-PT/Akt2.
Statistical analysis
Statistical analysis was performed using
the GraphPad Prism version 3.03 for Win-
dows (GraphPad Software). Significant dif-
ferences among groups were determined by
one-way ANOVA followed by Tukey test.
Results
Central leptin reduces food intake,
body weight, and adiposity
As expected, central leptin admin-
istration reduced the daily food in-
take, and this was accompanied by
body weight loss in these rats. More-
over, leptin treatment decreased by
26% and 37% the weights of eWAT
and rWAT, respectively, and accord-
ing to its well-known lipostatic func-
tion, central leptin infusion signifi-
cantly reduced TAG levels in plasma
and in WAT. Finally, in agreement
with our previous observations (29),
fasting plasma insulin levels were also
decreased compared with saline-
treated pair-fed control rats (Table 1).
Effects of central leptin on insulin
sensitivity and on glucose uptake
in WAT
To investigate the consequences of
central leptin treatment on the overall insulin sensitivity
weperformedan ipglucose tolerance test.As shown inFig.
1A, the insulin secretion in leptin-treated rats was signif-
icantly lower than in saline-infusedad libitumandpair-fed
control rats. Consistent with this, the insulin sensitivity
index, calculated as the ratio of glucose AUC to insulin
AUC, was improved significantly in leptin-treated rats.
This result implies that leptin increases the whole-body
insulin sensitivity.
Because leptin modulates the glucose utilization in a
tissue-specific manner, we analyzed the effects of the hor-
mone on 2-deoxyglucose uptake in WAT explants from
saline-treated pair-fed control and leptin-treated rats.
FIG. 1. Effects of central leptin administration on ip glucose tolerance test and glucose
uptake in WAT explants. A, Intraperitoneal glucose tolerance test was carried out after 7 d of
central leptin (Lep) 0.2 g/d or vehicle (SS and PF) infusion (rat groups 1–3, see Materials and
Methods) in overnight fasted rats before the test. Blood was taken from the tail at 0, 15, 30,
60, and 120 min after the glucose administration. Overall changes in glucose and insulin
during glucose tolerance test were calculated as the AUC. The ratio of glucose AUC to insulin
AUC was used as an index of whole body insulin sensitivity. Data are the mean  SEM of three
to four rats per group (**, P  0.05). B, Glucose uptake in WAT explants after unilateral
autonomic nervous system denervation (rat groups 4–5, see Materials and Methods). rWAT
explants were used for [3H]-2-deoxyglucose uptake measurements in the absence or presence
of 80 nM insulin stimulation for 10 min. Results are the mean  SEM of three to four rats per
group, made in triplicate (**, P  0.005; ***, P  0.001). SS, vehicle-infused ad libitum-fed
rats; PF, vehicle-infused per-fed rats; Lep, leptin-infused rats; Lep-d, leptin-infused in unilateral
denervated rats.
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Central leptin treatment had no effect on the basal but
significantly decreased the insulin-stimulated glucose up-
take in rWAT explants comparedwith saline-treated pair-
fed control rats (Fig. 1B). Similar results were observed in
eWAT (not shown). To investigate whether central leptin
effects onWATwere mediated by neural circuits, we per-
formed surgical denervation of the left rWAT, leaving the
contralateral intact right fat pad as an internal control. As
shown in Fig. 1B, local autonomic denervation abolished
the inhibitory effect of central leptin on glucose transport
and restored the insulin stimulation of glucose uptake in
rWAT.Because the effect of central leptin tookplace in the
face of unaltered circulating plasma leptin levels (Table 1),
this result suggests that leptin action in WAT is indeed
indirect and mediated by the autonomic nervous system.
We also examined the ability of insulin to induce the
translocation of GLUT4 from intracellular compartments
(LM) to the PM in eWATupon in vivo insulin stimulation.
In adipose tissue from saline-infused ad libitum and pair-
fed control rats, in vivo insulin administration stimulated
the GLUT4 translocation from LM to PM (Fig. 2). How-
ever, the ability of insulin to increase the amount of
GLUT4 insertion at the PM was prevented by leptin even
though the GLUT4 redistribution from LM was unaf-
fected (Fig. 2, A and B).
Central leptin inhibits early steps of in vivo insulin
signaling in WAT
To analyze the mechanism underlying the inhibitory
effect of central leptin on glucose uptake and GLUT4
translocation upon acute in vivo insulin stimulation, we
studied the effects of a 7-d central leptin infusion on early
steps of insulin signaling pathway
known to regulate these processes in
WAT, such as IR and IRS-1. At the
basal state we did not observe changes
in IR and IRS-1 tyrosine-phosphoryla-
tion after chronic leptin treatment (Fig.
3, A and B). However, leptin treatment
significantly augmented the basal con-
tent of IRS-1 phosphorylation on
Ser307 (Fig. 3C).
The intravenous acute insulin ad-
ministration stimulated both the IR au-
tophosphorylation and the IRS-1 ty-
rosine phosphorylation in ad libitum
and pair-fed control rats (Fig. 3, A and
B). In contrast, in chronic leptin-treated
rats insulin failed to promote the IR au-
tophosphorylation and the tyrosine
phosphorylationof IRS-1 (Fig. 3,A and
B) but further increased the content of
IRS-1 phosphorylation on the inhibi-
tory Ser307 (Fig. 3C).
Central leptin alters Akt phosphorylation in WAT
in response to in vivo insulin stimulation
Nextwe examined the effect of leptin treatment onAkt
phosphorylation inWATupon in vivo insulin stimulation.
In pair-fed rats, as expected, insulin administration stim-
ulated Akt Ser473 and Thr308 phosphorylation at the
PM, and this activated state of the enzymewasmaintained
at the cytoplasm fraction (Fig. 4, A–D). In contrast, leptin
treatment increased the basal Akt Ser473 phosphory-
lation in both compartments (Fig. 4, A and C) without
affecting basal Akt Thr308 phosphorylation (Fig. 4B).
Surprisingly, upon insulin stimulation of leptin-treated
rats, phosphorylation of Ser473 decreased near to the
basal levels of control rats at the PM (Fig. 4A). Our data
also indicate that the Akt distributed throughout the
cytoplasm is unresponsive to insulin in leptin-treated
rats (Fig. 4, C and D).
Effects of central leptin on IR, IRS-1, and GLUT4
mRNA and total protein levels in rat WAT
To further investigate the molecular mechanisms in-
volved in central leptin action on insulin signaling in
WAT, we examined the effects of a 7-d central leptin in-
fusion on the mRNA and total protein levels of IR iso-
forms, IRS-1, and GLUT4 in rat eWAT.
The IR occurs in WAT as two alternatively spliced iso-
forms, IR-A (exon 11) and IR-B (exon 11) (34). To
quantify the differential expression of IR-A and IR-B, spe-
cific primers were used in each case. Central leptin admin-
FIG. 2. Central leptin administration impairs the insulin-stimulated GLUT4 translocation to
the PM in WAT. After 7 d of central leptin (Lep) 0.2 g/d or vehicle (SS and PF) infusion, rats
(groups 1–3) were injected iv with insulin (Ins) (10 IU/kg body weight) or vehicle injection.
Thirty minutes after injection, the eWAT was removed and processed to analyze the amount
of GLUT4 in PM and LM fractions. The GLUT4 content in 100 g of PM (A) and 50 g of LM
(B) was determined by immunoblot. Representative immunoblots are shown. Results are the
mean  SEM of three to four rats per group (*, P  0.05; **, P  0.005; ***, P  0.001). SS,
vehicle-infused ad libitum-fed rats; PF, vehicle-infused per-fed rats; Lep, leptin-infused rats.
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istration did not affect either the gene expression of the IR
isoforms (Fig. 5D) or total IR protein levels (Fig. 5A) in
WAT.However, both IRS-1 (Fig. 5, B andD) andGLUT4
(Fig. 5, C and D) mRNA and total protein levels signifi-
cantly decreased in leptin-infused compared with pair-fed
rats.
Chronic central leptin treatment increases SOCS3
and resistin mRNA and protein levels in rat WAT:
effect of autonomic denervation
Having determined the effects of central leptin on early
steps of insulin signaling pathway involved in glucose up-
take in WAT, and because SOCS3 and resistin are two
potentially negative regulators of insulin signaling, we de-
cided to examine the expression levels of both proteins in
rWAT upon central leptin administra-
tion. Our results show that SOCS3
mRNA(Fig. 6C)andprotein levels (Fig.
6A) were increased in leptin-infused
compared with pair-fed control rats.
Moreover, a marked increase of 4.7-
fold in mRNA (Fig. 6C) and 3.6-fold in
resistin protein levels (Fig. 6B) was also
observed in leptin-infused rats com-
pared with the pair-fed ones. Central
leptin treatment also induced similar
changes in eWAT (Supplemental Fig. 1
published on The Endocrine Society’s
Journals Online web site at http://
endo.endojournals.org/).
We have demonstrated that surgical
autonomic denervation restored the in-
sulin-stimulated glucose uptake in
WAT in central leptin treated rats (Fig.
1B).Thus,wenext assessedwhetherde-
nervation of the rWAT would also at-
tenuate the up-regulation of SOCS3
and resistin expressionafter central lep-
tin administration. Surgical autonomic
denervation resulted in a modest but
statistically significant decrease in the
mRNA and, to a higher extent, in the
protein levels of both SOCS3 and resis-
tin (Fig. 6). In fact, upon denervation
SOCS3 protein levels were similar to
pair-fed control rats,whereas therewas
a1.7-fold decrease in resistin protein
levels. Collectively, these data support
that these proteins could contribute to
the inhibitory effect of central leptin on
glucose uptake in WAT.
Effect of resistin on glucose
uptake in WAT explants
Although central leptin administration for 7 d increases
resistinmRNAand protein levels inWAT (Fig. 6 and Sup-
plemental Fig. 1), interestingly, central leptin infusion did
not alter plasma resistin levels (Table 1). These data sug-
gest that resistin, acting nearby theWAT, is likely to cause
local but not systemic insulin resistance. To directly ad-
dress the effects of resistin on glucose uptake in this tissue,
we preincubated rWAT explants with resistin (200 ng/ml)
for 4h and then analyzed the glucose uptake in the absence
or presence of insulin. As shown in Fig. 7, no significant
differences were found in basal glucose uptake values
(14.39  1.5 vs. 16.35  1.8 pmol 2-deoxyglucose/mg
tissue, n  4; P not significant) in WAT explants prein-
cubated with or without resistin, respectively. However,
FIG. 3. Central leptin administration inhibits the in vivo insulin responsiveness of IR and IRS-1
at the PM of WAT. After 7 d of central leptin (Lep) 0.2 g/d or vehicle (SS and PF) infusion,
rats (groups 1–3) were injected iv with insulin (Ins) or vehicle. Thirty minutes after injection the
eWAT was removed and used for immunoblotting analysis in 75 g of PM using specific
antibodies. Representative immunoblots are shown. The data are expressed as ratio of
phosphorylated protein to the amount of each protein, respectively: IR-PY1146/IR (A), IRS-1-
PY/IRS-1 (B), and IRS-1-PSer307/IRS-1 (C). Densitometric results are the mean  SEM of three
to four rats per group (*, P  0.05; **, P  0.005; ***, P  0.001). SS, vehicle-infused ad
libitum-fed rats; PF, vehicle-infused per-fed rats; Lep, leptin-infused rats.
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there was a 37% significant decrease in the insulin-stim-
ulated glucose transport in WAT explants preincubated
with resistin compared with untreated controls (17.05 
2.5 vs. 26.87  3.1 pmol 2-deoxyglucose/mg tissue, re-
spectively; n 4; P 0.01). Although insulin did increase
glucose uptake above control in the presence of resistin the
magnitude of the response was significantly attenuated
(1.18-fold vs. 1.64-fold;P 0.01) in the presence or in the
absence of resistin, respectively, after insulin stimulation.
Discussion
Several studies have reported that central or peripheral
leptin treatment enhances whole-body insulin sensitivity
in terms of glucose metabolism but promotes insulin-re-
sistance in WAT (2–4). While the peripheral actions of
leptin are known to take place through leptin receptors,
the neural pathways and the neurochemical phenotypes of
the neurons constituting the autonomic nervous circuits
which transmit leptin signal toWAT are largely unknown
(35).Nevertheless, it is well established that central leptin,
independently of its effects on food intake, regulatesWAT
lipid metabolism by increasing lipolysis and suppressing
de novo lipogenesis (27, 29, 36). However, the mecha-
nisms underlying the inhibitory effect of central leptin on
the insulin-dependent glucose uptake inWAT,whichmay
contribute to decrease glucose availability for free fatty
acid (FFA) esterification and lipid deposition in this tissue,
are not completely understood.
In the present study we provide new insights on the
mechanisms by which central leptin regulates glucose up-
take in WAT: inhibition of insulin-stimulated tyrosine
FIG. 4. Central leptin administration alters the in vivo insulin-induced Akt phosphorylation in WAT. After 7 d of central leptin (Lep) 0.2 g/d or
vehicle (SS and PF) infusion, rats (groups 1–3) were injected iv with insulin (Ins) or vehicle. Thirty minutes after injection, the eWAT was removed
and used to analyze in PM and CYT fractions the Akt phosphorylation on Ser473 and Thr308 residues, respectively. Representative immunoblots
are shown. The data are expressed as ratio of PSer473/Akt (A and C) and PT308Akt /Akt (B and D) in 75 g of PM or 50 g of CYT, respectively.
Densitometric results are the mean  SEM of three to four rats per group (*, P  0.05; **, P  0.005; ***, P  0.001). SS, vehicle-infused ad
libitum-fed rats; PF, vehicle-infused per-fed rats; Lep, leptin-infused rats.
1372 Bonzo´n-Kulichenko et al. CNS Leptin and Glucose Uptake in WAT Endocrinology, April 2011, 152(4):1366–1377
phosphorylation of IR and IRS-1, suppression of Akt ac-
tivation, the down-regulation of the mRNA and protein
levels of both IRS-1 and GLUT4, and suppression of in-
sulin-stimulated GLUT4 insertion at the PM. As a result,
the glucose uptake inWATwas impaired in central leptin-
treated rats, an effect that was dependent of an intact au-
tonomic nervous system. In fact, surgical denervation of
WAT abolished the inhibitory effect of leptin on glucose
uptake and restored the insulin stimulation of glucose
transport in this tissue. Our results agree with previous
data showing that the inhibition of WAT lipogenesis in
rats by central leptin is lost after surgical WAT denerva-
tion (27). The fact that plasma leptin does not increase
after chronic central leptin administration excludes that
the observed effects of this treatment were attributable to
peripheral actions of the hormone.
A major finding of the present work is that the effects
of central leptin on insulin signaling in WAT were paral-
leledwith themarkedup-regulationof SOCS3and resistin
mRNA and protein levels in WAT upon central leptin
administration. Because plasma resistin levels were not
modified upon central leptin treatment
but were significantly increased in
WAT, these data suggest that central
leptin, increasing resistin and SOCS3
levels in WAT, could contribute to tis-
sue-specific but not systemic insulin re-
sistance. Supporting this contention, it
has been reported that resistin, induc-
ing SOCS3 expression, attenuates early
steps of insulin signaling pathway (IR
autophosphorylation, IRS-1 tyrosine
phosphorylation, and Akt activation)
in 3T3-L1 adipocytes, while the inhibi-
tion of SOCS3 function, expressing a
dominant negative SOCS protein, pre-
vented resistin from antagonizing insu-
lin action in adipocytes (22).
The inhibitory effect of central leptin
on insulin-stimulated glucose uptake in
WAT could be mediated by the mela-
nocortin receptor (MCR) system. In
fact, the intracerebroventricular infu-
sion of SHU9119, a MCR antagonist,
significantly decreased the glucose up-
take in brownadipose tissue, heart, and
skeletal muscle while increasing glu-
cose uptake as well as TAG synthesis
and deposition in WAT in rats, under
clamp conditions (37). On the other
hand, the intracerebroventricular injec-
tion of SHU9119 abolished the stimu-
latory effect on glucose uptake in pe-
ripheral tissues induced by leptin injection into the
ventromedial hypothalamus except in WAT (38). These
results suggest that MCR system is necessary for the con-
trol of glucose uptake by peripheral tissues induced by
central leptin.
We have previously shown that in hyperleptinemic
aged insulin resistant rats a reduction in the expression of
the IR-B isoform occurs, without changes in IR-A (34).
Thus, we hypothesized that chronic central leptin could
affect the mRNA levels of the IR isoforms. Central leptin
administration for 7 d did not affect the IR isoform gene
expression or total IR protein levels but inhibited the in
vivo insulin stimulation of IR autophosphorylation. Our
data also indicate that chronic central leptin inhibited the
insulin-stimulated IRS-1 tyrosine phosphorylation, in-
creased IRS-1 phosphorylation on Ser307, which is well
known to promote IRS-1 degradation (39), and this was
accompanied by reduced IRS-1mRNA and protein levels.
These changes occurred in parallel with the marked up-
regulation of SOCS3 upon central leptin administration
FIG. 5. Effect of centrally infused leptin on IR, IRS-1, and GLUT4 mRNA and total protein
levels in WAT. The eWAT of rat (groups 1–3) infused for 7 d with central leptin (Lep) 0.2 g/d
or vehicle (SS and PF) was removed and processed to analyze total protein content and mRNA
levels of IR-, IRS-1, and GLUT4. IR- (A), IRS-1 (B), and GLUT4 (C) protein content in 70 g
of total extract was determined by immunoblotting using specific antibodies for each protein.
Representative immunoblots are shown. The data are expressed as ratio of each protein after
correction for -actin. Densitometric results are the mean  SEM of three to four rats per
group (*, P  0.05; **, P  0.005). D, Changes in mRNA levels in eWAT after central leptin
treatment using 18S rRNA as the invariant control. The results are the mean  SEM of three to
four rats per group (*, P  0.05; **, P  0.005). SS, vehicle-infused ad libitum-fed rats; PF,
vehicle-infused per-fed rats; Lep, leptin-infused rats.
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reported herein. SOCS3 is known to act as a negative reg-
ulator of insulin signaling, inhibiting the insulin-stimu-
lated tyrosine phosphorylation of IR and IRS-1 (19, 20,
40), and promoting IRS-1 protein degradation (39, 41).
Although we have not directly addressed IRS-1 protein
degradation, our results suggest that central leptin could
drive IRS-1 to proteasome degradation. In fact, central
leptin promotes a2.2-fold higher decrease in IRS-1 total
protein than in mRNA levels. Taken together, our results
demonstrate that central leptin inhibits early steps of the
signaling pathway normally used by insulin in the regu-
lation of glucose uptake in WAT.
Full activation of Akt by insulin requires hierarchical
phosphorylation of two residues, Thr308 and Ser473, by
the PDK1 protein kinase and the Rictor-mammalian tar-
get of rapamycin complex (mTORC)2, respectively (42,
43). Thus, we next examined the effect of central leptin on
in vivo insulin stimulation of Akt phosphorylation and
GLUT4 translocation to the PM. It has previously been
reported that Akt Ser473-phosphorylation in liver and
muscle in rodentswas unaltered (13) or
increased upon peripheral leptin treat-
ment in vivo (44, 45). The results pre-
sented herein demonstrate that central
leptin elicits an increase in the basal con-
tent of Akt Ser473-phosphorylation and
inhibits normalAkt activation after insu-
lin stimulation. Consequently, central
leptin impairs the in vivo insulin-stimu-
lated GLUT4 insertion at the PM in
WAT. Moreover, leptin decreases
GLUT4mRNAandprotein levels,which
agrees with previous data in sc leptin-
treated rats (4). As a result, the insulin-
stimulated glucose uptake in WAT was
impaired in central leptin-treated rats.As
themain role of insulin inWAT is to pro-
mote the incorporation of glucose into
TAG, the inhibition of glucose uptake by
central leptin may contribute to regulate
glucoseavailability forFFAesterification
and to control lipid deposition in this tis-
sue. In addition, there is evidence report-
ing that central leptin administration
decreased both lipoprotein lipase expr-
ession and FFA uptake inWAT (27). All
these observations, together with the de-
crease in the visceral fatweight and in the
content ofTAG inWAT in leptin-treated
rats reported herein, are consistent with
the putative function of the hormone in
regulating adiposity.
In addition to the role of Akt on in-
sulin-stimulated glucose uptake, it has been shown that
the pharmacological inhibition of Akt resulted in a reduc-
tion in basal and insulin-stimulated lipogenesis in isolated
rat adipocytes (46). Thus, the suppression of insulin-stim-
ulatedAkt activation in leptin-treated rats reported herein
could be consistent with previous data showing the inhi-
bition of WAT lipogenesis by central leptin (27). More-
over, insulin signaling via PI3K/Akt activates mTORC1
leading to increased hepatic lipogenesis (47). In addition,
theactivationofmTORC1signaling in3T3-L1adipocytes
by ectopic expression of Rheb increases de novo lipogen-
esis and promotes intracellular accumulation of TAG,
while the inhibition of mTORC1 signaling by rapamycin
or by knock down of raptor stimulates lipolysis primarily
via activation of ATGL expression (48). Consequently, it
can be speculated that the inhibition by central leptin of
insulin-stimulated Akt activation reported herein could
affect mTORC1 activation and ATGL expression in
WAT. In support of this, we have previously shown that
FIG. 6. Central leptin administration increases SOCS3 and resistin expression in rWAT. After
unilateral autonomic nervous system denervation, the rWAT of rat (groups 4–5) infused for
7 d with central leptin (Lep) 0.2 g/d or vehicle (PF) was removed and processed to analyze
total protein content levels of SOCS3 (A) and resistin (B) in 70 g of total extract using
specific antibodies. Representative immunoblots are shown. The data are expressed as ratio of
each protein after correction for -actin. Densitometric results are the mean  SEM of three to
four rats per group (*, P  0.05; **, P  0.005). C, Changes in SOCS3 and resistin mRNA
levels in rWAT after central leptin treatment using 18S rRNA as the invariant control. The
results are the mean  SEM of three to four rats per group (*, P  0.05; **, P  0.005). PF,
vehicle-infused per-fed rats; Lep, leptin-infused rats; Lep-d, leptin-infused in unilateral
denervated rats.
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central leptin administration significantly increased
ATGL expression in WAT (29) and impaired the insulin-
mediated phosphorylation of bothmTOR and S6K in this
tissue (unpublisheddata).These results are consistentwith
the inhibition by leptin of the insulin-stimulated Akt ac-
tivation reported herein. Nevertheless, these suggestions
need furtherworkbefore a final conclusionmaybedrawn.
Several hormones andcytokines associatedwith insulin
resistance, such as leptin, insulin, IL-6, TNF-, and resis-
tin, induce SOCS3 expression acting directly on adi-
pocytes in vitro (12,20–22).BecauseSOCS3expression in
WAT in mice is induced after an ip resistin injection (22),
we hypothesized that resistin expression inWAT could be
up-regulated by central leptin. Contrary to previous data
showing either no change or decreased resistin mRNA
levels in WAT upon central leptin infusion (49, 50), we
found that central leptin, infused at a 50-fold lower con-
centration than in previous studies (49, 50), markedly in-
creased resistin mRNA and total protein levels in WAT,
without affecting plasma resistin levels. Althoughwe can-
not establish a direct association between central leptin
effects on insulin signaling and resistin up-regulation in
WAT, several lines of evidences suggest that resistin, act-
ing in an autocrine/paracrine manner, might lead toWAT
insulin resistance. First, local autonomic denervation of
WAT restored the insulin stimulation of glucose uptake,
and this was paralleled by the marked decrease in SOCS3
and resistin protein levels in this tissue. Although the re-
sistin protein contentwas still higher in leptin-treated than
in pair-fed control rats upon denervation, it can be argued
that resistin, at the protein levels reported herein, might
not be sufficient to inhibit the glucose transport in re-
sponse to insulin. In fact, it has been reported that the
complete inhibition of insulin-stimulated glucose uptake
wasobservedbetween100 to500nMresistin inL6 skeletal
muscle cells (51). Because the immunoblot analyses pro-
vide relative protein data, additional studies have to be
done before a final conclusion may be drawn. Second, in
agreementwith previous data analyzing the direct effect of
resistin on glucose uptake in 3T3-L1 adipocytes (52) and
L6 cells (53) or in 3T3-L1 adipocytes stably expressing
resistin (54), we demonstrate that resistin decreased insu-
lin stimulation of glucose uptake in WAT explants. This
observation provides direct support for the evidence that,
upon central leptin administration, the up-regulation of
resistin levels in WAT can contribute to the inhibition of
the insulin-stimulated glucose uptake in this tissue. Fi-
nally, our data are consistent with previous reports show-
ing that resistin inhibits the early steps of insulin signaling
pathway involved in glucose uptake in 3T3-L1 adipocytes
(52, 54) and L6 cells (53). Nevertheless, the contribution
ofother factorspromoting insulin resistance inWATupon
central leptin administration should be taken into ac-
count. In fact, central leptin increases both SOCS3 and
IL-6mRNA levels inWAT (27). Thus, we suggest that the
adipose-derived factor resistin and the cytokine suppres-
sor SOCS3 could be implicated in the local attenuation of
the insulin action in WAT upon chronic central leptin
treatment.
In conclusion, we have shown that leptin, acting at a
central level, negatively modulates early steps of the sig-
naling pathway normally used by insulin in the regulation
of glucose uptake in WAT. Because local autonomic de-
nervation of WAT abolished the inhibitory effect of cen-
tral leptin on glucose transport and decreased SOCS3 and
resistin levels in this tissue, our data also suggest that re-
sistin might be a mediator of central leptin antagonism of
insulin action in WAT. Because glucose uptake from ex-
tracellular sources is an important step to promote TAG
formation and de novo lipogenesis inWAT, the inhibition
of glucose uptake by central leptin may contribute to reg-
ulate excessive fat mass enlargement, a factor known for
playing a key role in the development of overall insulin
resistance.
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